Pfizer (PFE) : Central Bank Trust Co reduced its stake in Pfizer by 1.72% during the most recent quarter end. The investment management company now holds a total of 54,753 shares of Pfizer which is valued at $1,837,511 after selling 956 shares in Pfizer , the firm said in a disclosure report filed with the SEC on Oct 7, 2016.Pfizer makes up approximately 0.52% of Central Bank Trust Co’s portfolio.
Other Hedge Funds, Including , Catawba Capital Management Va reduced its stake in PFE by selling 3,525 shares or 1.77% in the most recent quarter. The Hedge Fund company now holds 195,851 shares of PFE which is valued at $6,572,760. Pfizer makes up approx 1.58% of Catawba Capital Management Va’s portfolio.Lifeplan Financial Group Inc boosted its stake in PFE in the latest quarter, The investment management firm added 311 additional shares and now holds a total of 13,125 shares of Pfizer which is valued at $444,938. Pfizer makes up approx 0.31% of Lifeplan Financial Group Inc’s portfolio.Stillwater Investment Management boosted its stake in PFE in the latest quarter, The investment management firm added 1,194 additional shares and now holds a total of 70,377 shares of Pfizer which is valued at $2,385,780. Pfizer makes up approx 1.30% of Stillwater Investment Management’s portfolio.Washington Trust Bank boosted its stake in PFE in the latest quarter, The investment management firm added 4,292 additional shares and now holds a total of 50,891 shares of Pfizer which is valued at $1,725,205. Pfizer makes up approx 0.41% of Washington Trust Bank’s portfolio.Cullinan Associates Inc reduced its stake in PFE by selling 12,670 shares or 3.71% in the most recent quarter. The Hedge Fund company now holds 328,553 shares of PFE which is valued at $11,137,947. Pfizer makes up approx 0.96% of Cullinan Associates Inc’s portfolio.
Pfizer closed down -0.09 points or -0.27% at $33.56 with 1,48,19,706 shares getting traded on Friday. Post opening the session at $33.7, the shares hit an intraday low of $33.42 and an intraday high of $34 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, Pfizer reported $0.64 EPS for the quarter, beating the analyst consensus estimate by $ 0.02 according to the earnings call on Aug 2, 2016. Analyst had a consensus of $0.62. The company had revenue of $13147.00 million for the quarter, compared to analysts expectations of $13013.24 million. The company’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.56 EPS.
Investors should note that on Sep 22, 2016, Pfizer announced a cash dividend of $0.3000. The company’s management has announced Nov 9, 2016 as the ex-dividend date and fixed the record date on Nov 11, 2016. The payable date has been fixed on Dec 1, 2016.
Pfizer Inc. is a global biopharmaceutical company. The Company is engaged in discovering developing and manufacturing of healthcare products. Its products include Lyrica the Prevnar family of products Enbrel Celebrex Lipitor Viagra Zyvox Sutent EpiPen Toviaz Tygacil Rapamune Xalkori Inlyta Norvasc BeneFIX Genotropin and Enbrel among others. It operates in three segments: Global Innovative Pharmaceutical segment (GIP) Global Vaccines Oncology and Consumer Healthcare segment (VOC) and Global Established Pharmaceutical segment (GEP). GIP is focused on developing registering and commercializing medications in therapeutic areas such as inflammation cardiovascular/metabolic neuroscience and pain rare diseases and women’s/men’s health. VOC focuses on the development and commercialization of vaccines and products for oncology and consumer healthcare. GEP includes its sterile injectable products and bio similar development portfolio. Its subsidiary is Hospira Inc.